Rhode Island House Bill H5625

Rhode Island 2025 Regular Session

• Introduced: 2/26/25
• Refer: 2/26/25
• Report Pass: 3/27/25
• Engrossed: 4/10/25

Caption

Removes the sunset provision of all statutory law requiring coverage for the treatment of pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections and pediatric acute onset neuropsychiatric syndrome.

Impact

The continuation of mandated coverage under H5625 is expected to extend critical health benefits to children diagnosed with these specific pediatric autoimmune conditions. Under the existing law, health insurance carriers are required to provide this coverage within Rhode Island and may also be obligated to continue coverage for services outside the state if such treatment is unavailable within their network. As a result, this can increase the overall accessibility of medical care and treatment options for families in need.

Summary

House Bill H5625 aims to remove the sunset provision, thereby extending the statutory requirement for health insurance coverage for the treatment of pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections and pediatric acute onset neuropsychiatric syndrome. Previously set to expire on December 31, 2025, this legislation seeks to mandate continued coverage for affected children under group health insurance policies in Rhode Island. The bill enhances access to necessary treatments, which include specific therapies such as intravenous immunoglobulin therapy.

Contention

Debate around H5625 may focus on the financial implications of extended coverage on health insurance carriers and the overall healthcare system. While proponents advocate for the essential nature of continued coverage for affected children, critics may voice concerns over potential increased costs to insurers, which could lead to higher premiums for policyholders. The need for a cost-benefit analysis by the health insurance commissioner, due by January 1, 2025, will further assess whether extending this coverage results in net savings or added financial burdens for both insurance companies and policyholders.